To position istaroxime for Phase 3 readiness, WINT launched the small Phase 2 study in SCAI Stage C. SCAI Stage C cardiogenic shock is a more severely ill patient population than the participants ...
MyChesCo on MSN5mon
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updateswe plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study as well as provide guidance on our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback